Dyadic International
Logotype for Dyadic International Inc

Dyadic International (DYAI) investor relations material

Dyadic International Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Dyadic International Inc
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • First direct commercial sales of recombinant transferrin and DNase I established a new product revenue channel, though initial sales were not material; partner launches and distribution also advanced.

  • Commercialization remains slower than planned as customer qualification takes longer, while strategy emphasizes partnerships, licensing and supply agreements to scale with less capital investment.

  • C1 biopharma programs advanced into preclinical animal studies, but substantial doubt about the ability to continue as a going concern and constrained financing remain central concerns.

Financial highlights

  • Q3 revenue was $449,101, down 61.4% YoY from $1.16 million, primarily due to lower grant and R&D collaboration revenue; 9M revenue was $2.52 million, essentially flat YoY.

  • Q3 revenue comprised $276,372 in grants, $162,318 in R&D revenue and $10,411 in license and milestone revenue; 9M grant revenue was $1.60 million.

  • Q3 operating loss was $1.81 million versus $1.93 million; net loss was $1.36 million, or $0.04/share, versus $1.98 million, or $0.06/share.

  • 9M operating loss was $5.77 million versus $5.66 million; net loss was $5.44 million, or $0.15/share, versus $5.80 million, or $0.18/share.

  • Q3 cost of revenue fell 63.4% to $375,115; internal R&D expense fell 24.8% to $429,945 and G&A fell 2.1% to $1.45 million.

Outlook and guidance

  • The $225,000 Inzymes milestone for the October commercial sale of Dapibus-produced camel chymosin is expected to be recognized as Q4 2026 revenue.

  • Gates-funded RSV and malaria antibody animal-study results are expected in Q1 2027; further development depends on results and external funding.

  • Management expects operating losses and negative operating cash flows to continue; unrestricted cash, cash equivalents and investments, net of unpaid offering costs, were expected to fund operations for seven months at the 9M cash-use rate.

  • Financing, grant funding, expanded product sales, licensing, partnerships and supply arrangements are being pursued, with execution and timing uncertain.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Dyadic International earnings date

Logotype for Dyadic International Inc
Q4 202625 Mar, 2027
Dyadic International
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Dyadic International earnings date

Logotype for Dyadic International Inc
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Dyadic International Inc. is a biotechnology company specializing in the development and commercialization of technologies for gene expression and protein production. The company’s primary platform, the C1 gene expression system, is used to produce enzymes and proteins for various industries, including biopharmaceuticals, vaccines, and industrial applications. Dyadic focuses on leveraging its proprietary technology to accelerate the development of biologics and other biotechnological products, aiming to improve production efficiency and scalability. The company is headquartered in Jupiter, Florida, and its shares are listed on the NASDAQ.